Fibrosis-related gene expression in the prostate is modulated by doxazosin treatment

Life Sci. 2012 Dec 17;91(25-26):1281-7. doi: 10.1016/j.lfs.2012.09.017. Epub 2012 Oct 12.

Abstract

Aims: To gain new insights into the molecular mechanisms of action of doxazosin, we investigated the prostatic stroma ultrastructure and the expression of genes involved with fibrosis, such as collagen type I and III (COL1A1 and COL3A1, respectively) and TGF-beta 1, in the rat ventral prostate.

Main methods: Adult Wistar rats were treated with doxazosin (25mg/kg/day), and the ventral prostates were excised at 7 and 30days after treatment. Untreated rats were controls. Ventral prostates were subjected to ultrastructural, immunohistochemical, biochemical and molecular analyses.

Key findings: Doxazosin-treated prostates showed thickened bundles of collagen fibrils, activated fibroblasts, enlarged neurotransmitter vesicles and increased tissue immunostaining for collagen type I and type III when compared to untreated prostates. After 7 and 30days of doxazosin treatment mRNA expression of COL1A1 and COL3A1 was significantly increased and reduced, respectively, compared to the control group. TGF-beta 1 mRNA and protein levels were increased after 7days of doxazosin treatment, whereas only mRNA levels remained increased after 30days of treatment.

Significance: Our data suggest that relaxation of smooth muscle cells by alpha-blockers interferes with the mechanical dynamics of the prostatic stroma extracellular matrix components, generating a pro-fibrotic effect probably via the TGF-beta 1 signaling pathway. Long term treatment with doxazosin may also lead to a reduced turnover of extracellular matrix components. Our results add to a better understanding of the molecular mechanisms behind the effects of alpha-blockade on prostatic histoarchitecture and the response to treatment for benign prostatic hyperplasia.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic alpha-1 Receptor Antagonists / administration & dosage
  • Adrenergic alpha-1 Receptor Antagonists / pharmacology*
  • Animals
  • Collagen Type I / genetics
  • Collagen Type I, alpha 1 Chain
  • Collagen Type II / genetics
  • Collagen Type III / genetics
  • Doxazosin / administration & dosage
  • Doxazosin / pharmacology*
  • Extracellular Matrix / drug effects
  • Extracellular Matrix / metabolism
  • Fibrosis
  • Gene Expression Regulation / drug effects*
  • Male
  • Myocytes, Smooth Muscle / drug effects
  • Myocytes, Smooth Muscle / metabolism
  • Prostate / pathology*
  • RNA, Messenger / metabolism
  • Rats
  • Rats, Wistar
  • Signal Transduction / drug effects
  • Time Factors
  • Transforming Growth Factor beta1 / metabolism*

Substances

  • Adrenergic alpha-1 Receptor Antagonists
  • COL3A1 protein, rat
  • Collagen Type I
  • Collagen Type I, alpha 1 Chain
  • Collagen Type II
  • Collagen Type III
  • RNA, Messenger
  • Transforming Growth Factor beta1
  • Doxazosin